Compare · DFTX vs SMFL
DFTX vs SMFL
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Smart for Life Inc. (SMFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and SMFL operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $4.71B.
- Over the past year, DFTX is up 345.2% and SMFL is up 0.0% - DFTX leads by 345.2 points.
- DFTX has hit the wire 6 times in the past 4 weeks while SMFL has been quiet.
- DFTX has more recent analyst coverage (5 ratings vs 0 for SMFL).
- Company
- Definium Therapeutics Inc.
- Smart for Life Inc.
- Price
- $43.14+0.54%
- $0.83-17.00%
- Market cap
- $4.71B
- -
- 1M return
- +2.42%
- +0.00%
- 1Y return
- +345.20%
- +0.00%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 6
- 0
- Recent ratings
- 5
- 0
Smart for Life Inc.
Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements; dietary supplements; nutritional supplements for athletes and active lifestyle consumers comprising powders, tablets, and soft gels; and various nutritional supplements. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Miami, Florida.
Latest DFTX
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
Latest SMFL
- SEC Form 10-Q filed by Smart for Life Inc.
- SEC Form 10-Q filed by Smart for Life Inc.
- SEC Form 25-NSE filed by Smart for Life Inc.
- Smart for Life Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Amendment: SEC Form SC 13G/A filed by Smart for Life Inc.
- SEC Form NT 10-Q filed by Smart for Life Inc.
- Smart for Life Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Smart for Life Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Smart for Life Reports Significant Balance Sheet Improvement; Achieves Over $9.4 Million in Positive Net Stockholders' Equity Following Successful Restructuring Efforts
- Smart for Life Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing